Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study BioSpacePemvidutide showed a "highly statistically significant" treatment effect in patients with alcohol use disorder.Metabolic & GLP-1Read full story pharminent July 28, 2026 (Last updated: July 30, 2026) BioSpace Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK to quit Stevenage for new R&D site in CambridgeNext: GSK Unveils Three-Year Restructuring to Fund Late-Stage R&D Ahead of Patent Cliff Related Stories Clinical Data Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug pharminent July 22, 2026 Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail pharminent July 17, 2026 Clinical Data AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug pharminent July 15, 2026
